Analysts recommend monitoring sector ETF movements, as flows into medical device funds often precede short‑term rallies in BSX stock forecast trajectories. Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance. In terms of earnings estimate revisions for Boston Scientific, the Zacks Consensus Estimate for the current year has increased 2.7% over the past month to $2.85. BSX stock forecast sentiment remains bullish after the company’s earnings beat consensus in its April 2024 report, fueled by strong launches in minimally invasive surgery products. Wall Street models project mid‑single‑digit EPS growth into FY